Jessica Hergert

Michael Wang, MD, discusses the implications of the ZUMA-2 trial for patients with relapsed/refractory mantle cell lymphoma and other targeted therapies on the horizon.

Gregory A. Otterson, MD, discusses the utility of immunotherapy in squamous non–small cell lung cancer and targeted the evolution of targeted therapy in biomarker-driven disease.

Jonathan E. Brammer, MD, discusses the role of minimal residual disease and transplant in acute lymphoblastic leukemia, as well as the introduction of CAR T-cell therapy and other novel agents to the armamentarium.

Michael Wang, MD, discusses the ZUMA-2 trial and the potential impact of CAR T-cell therapy on the treatment paradigm in mantle cell lymphoma.

Joseph Wynne, MD, discusses ongoing studies with blinatumomab and CAR T-cell therapy in acute lymphoblastic leukemia, as well as the importance of assessing minimal residual disease in this space.

Karl M. Kilgore, PhD, discusses how results of real-world analysis may impact the utilization of CAR T-cell therapy for older patients with relapsed/refractory diffuse large B-cell lymphoma.

In an era of personalized medicine in oncology, monoclonal antibodies, bispecific T-cell engagers, and CAR T-cell therapies are revolutionizing patient outcomes in multiple myeloma.

Joseph A. Sparano, MD, discusses using gene expression profiles as a means to guide therapy in breast cancer.

Wayne A. Marasco, MD, PhD, discusses the intricacy of engineering CAR T cells and the early data he has observed with CAR T-cell therapy in renal cell carcinoma.